研究者業績
  1. 研究者検索結果一覧
  2. 菅野 武

菅野 武

カンノ タケシ  (Kanno Takeshi)

基本情報

所属
自治医科大学 医学部　医学教育センター　医療人キャリア教育開発部門 教授 (特命教授)
東北大学 大学院医学系研究科　消化器病態学分野 准教授
学位
博士（医学）(2015年3月 東北大学)
J-GLOBAL ID
201801017707199790
researchmap会員ID
B000302281

＜臨床経験に立脚した、社会の問題を解決するエビデンスの構築と、シミュレータ開発および学習法の開発＞

1. 地域医療の経験を背景にし、内科学一般とくに消化器内科学を研究の基盤としています。医学博士は「東日本大震災後の消化性潰瘍の増加とその特徴」に関する臨床研究で取得し、精神的ストレスは、消化性潰瘍の独立した成因であり、災害時潰瘍出血の危険因子となることを報告しました。現在も臨床の課題を克服すべく、コホートやRCTを含む臨床研究とシステマティックレビューを実施し、エビデンスの実臨床への還元を目指しています。2018年EBCP workshop (Prof. Gordon Guyyatほか)に参加し、2019年7月よりCochrane Upper GI and Pancreatic diseases(その後Cochrane Gutに名称変更)のEditorを5年間務めました。2024年より月刊地域医学誌の編集委員2026年より副編集長を委嘱されています。COVID-19状況下の意思決定支援として、Prof. Paul Moayyedの指導で、免疫不全者や小児におけるワクチン効果に関してのエビデンス集積を行いました。(COVID-END: COVID-19 Evidence Network to support Decision-making in Canada)。

東日本大震災時の出血性潰瘍増加をきっかけに、出血を伴う観血的内視鏡処置の学習環境の課題を明らかとし、そこから新規シミュレータ開発とそれらを用いた問題解決型シミュレーション教育の推進をしています。
医学教育学会主催の第43回富士研ＷＳに参加し、2023年4月から自治医科大学医学教育センター医療人キャリア教育開発部門を担当し、卒前卒後をつなぐキャリア教育を模索しています。また2．と関連して災害の経験を通した医療者としてのプロフェッショナリズムに関する講義を継続的に行っております。

 

＜災害時の経験と人脈をきっかけに、領域横断的な災害医療人材の育成＞
2. 2008年岩手宮城内陸地震(M7.2)では震源地に近接する栗原中央病院での急性期トリアージと治療、DMAT受け入れを経験しました。また2011年東日本大震災(M9.0)では、南三陸町公立志津川病院で勤務医として15mを超える地震津波災害に被災、患者・住民避難とその後の災害医療体制構築に関わりTIME誌「世界で最も影響力のある100人」に選出されました。以降、災害医療領域の中でこれまで重視されてこなかった支援を受け止める「受援」の在り方を提言しています。さらに、被災した人間として困難に向き合うレジリエントな社会を目指し、国内外で経験と知見を共有する講演活動・いのちの教育を継続しています。2025年現在で講演はのべ300回を超え、2万4千人超の聴講者へメッセージを伝えています。
2019年10月より文部科学省補助金事業（平成30年度選定）「課題解決型高度医療人材養成プログラム」"コンダクター型災害保健医療人材の養成プログラム"とその後継事業の運営業務に携わり、社会に提案できる医療人材育成を進めています。2024年1月の能登半島地震においても自治医科大学同窓会支援チームの立ち上げおよび事務局を担当し受援体制構築と被災地内医療機関の疲弊を防ぐ取り組みを主導しました。

 

 ＜クロスアポイントメントを用いた大学×大学連携／臨床×教育連携＞

3. 文部科学省が推進するクロスアポイントメント制度の事例として、2023年4月より東北大学大学院医学系研究科消化器病態学分野でのシミュレータ研究開発を准教授として継続し、自治医科大学医学教育センター医療人キャリア教育開発部門の特命教授として両方常勤職を務め、領域横断的かつ大学横断的な活動を実践すべく取り組んでいます。どちらの所属においても周囲の理解と協力の下でいくつものプロジェクトを進めていますので、研究力や医工連携に強い東北大学と、臨床と医療人教育に強みのある自治医科大学の連携構築としても発展できるよう努めています。

産学連携で開発しているシミュレータ Medical Rising STAR シリーズ（動画）https://www.youtube.com/playlist?list=PLYyDSR_h1X0yyqqgRpVUd6erdvJKoXqIA

 

 

＜リンク先：シミュレータ開発におけるプレスリリース記事＞

侵襲的内視鏡手技シミュレータの社会実装 デンカと東北大学の産学連携「Medical Rising STAR®」プロジェクト

https://www.tohoku.ac.jp/japanese/2023/04/press20230425-01-denka.html

出血合併症の再現を含む 胆膵内視鏡シミュレータモデルを開発 産学連携「Medical Rising STAR」プロジェクト第2弾

https://www.tohoku.ac.jp/japanese/2024/02/press20240219-02-mrs.html

早期消化管がんのESD（内視鏡的粘膜下層剥離術）シミュレータモデルを開発 産学連携「Medical Rising STAR」プロジェクト第3弾の成果

https://www.tohoku.ac.jp/japanese/2026/01/press20260114-01-ESD.html

 

＜リンク先：TEDxTaipei 2014講演 被災とレジリエンスについて＞
http://tedxtaipei.com/talks/2014-takeshi-kanno/
※メディア関連出演の記録は社会貢献活動欄の末尾に、東北大学医学部広報一條様のご助力で一覧を作成し掲載しています。
＜リンク先：コンダクター型災害保健医療人材の養成プログラム＞
https://www.dcnd.hosp.tohoku.ac.jp/

研究キーワード

 5

研究分野

 3

経歴

 11
もっとみる

学歴

 2

委員歴

 11
もっとみる

受賞

 7
もっとみる

論文

 124
  • Satoshi Sato, Jun Watanabe, Takeshi Kanno, Keigo Misawa, Hiromi Sekiguchi, Tomonori Yano, Atsushi Masamune, Tomoari Kamada
    Digestion 1-1 2026年9月5日  査読有り責任著者
    INTRODUCTION: Helicobacter pylori eradication is clinically important in patients on hemodialysis (HD), who are at risk for serious gastrointestinal complications. However, altered drug metabolism and antibiotic resistance in patients on HD complicate H. pylori eradication. This study aimed to perform a network meta-analysis to synthesize existing evidence on the efficacy and safety of H. pylori eradication regimens in patients on HD. METHODS: We searched MEDLINE, the Cochrane Library, EMBASE, Ichushi-web, ICTRP, and ClinicalTrials.gov. Two reviewers independently selected randomized controlled trials that evaluated H. pylori eradication therapy in patients undergoing HD. We performed a frequentist random effects network meta-analysis. The primary outcome was eradication rate, and the secondary outcomes were treatment completion rates and all adverse events. We used CINeMA to assess the confidence in the evidence. The study protocol was registered at OSF (https://osf.io/gn978/). RESULTS: Ten trials involving 481 patients were included in the analysis. Seven eradication regimens were compared: six concomitant and one sequential regimen. Relative to standard-dose proton pump inhibitor/clarithromycin/amoxicillin regimens (PAC), the evidence is very uncertain about the effect of the proton pump inhibitor/clarithromycin regimen on the eradication rate (odds ratio, 0.11; 95% confidence interval, 0.01-1.07). For reduced-dose PAC (in which clarithromycin or amoxicillin is dose-reduced), alternative regimens (with azithromycin, metronidazole, or levofloxacin), and sequential regimens, the estimates were too imprecise to determine whether a difference from PAC exists (low certainty). Treatment completion rates were generally favorable (83-100%), and adverse events were most frequent with standard-dose PAC (45%). CONCLUSIONS: Reduced-dose PAC and alternative and sequential regimens may be considered for H. pylori eradication in patients on HD.
  • Yutaka Hatayama, Takeshi Kanno, Tetsuya Takikawa, Ryotaro Matsumoto, Yutaro Arata, Suguo Suzuki, Kaname Uno, Kazuhiro Kikuta, Tomoyuki Koike, Atsushi Masamune
    DEN Open 7(1) 2026年9月1日  責任著者
    ABSTRACT Objectives Endoscopic sphincterotomy (EST) is a high‐risk procedure with a steep learning curve. We previously developed a novel dry simulator capable of reproducing bleeding after an inappropriate incision. This study aimed to evaluate the effectiveness of a structured educational program using the simulator within the Bethesda Endoscopic retrograde cholangiopancreatography (ERCP) Skill Assessment Tool (BESAT) framework. Methods This prospective study implemented a standardized training sequence: (1) preliminary video‐based learning; (2) an initial attempt at cannulation, EST, and biliary stone extraction; (3) BESAT‐based expert feedback focusing on six key technical tips; (4) a second attempt. The primary outcome was the change in EST success, which is defined by an incision in the 11–12 o'clock direction with appropriate length and no bleeding, before and after feedback. Secondary outcomes were procedure completion, including stone removal within 15 min, and subjective self‐assessments of procedural understanding and confidence. Results Thirty gastroenterology trainees were enrolled. The EST success rate increased from 43.3% to 76.7% ( p < 0.05). The completion rate of the procedure tended to increase from 46.7% to 70.0% ( p = 0.07). Subjective self‐confidence improved from a median of 24.0–53.0 after training and remained at 53.5 at 3 months; other self‐assessed domains also improved and were sustained. Post‐hoc analysis showed that initial EST success was associated with >50 prior ERCP cases (odds ratio = 7.86, 95% confidence interval: 1.31–47.0, p < 0.05). Conclusions A structured simulator‐based program enables trainees to experience failure and improves simulator‐based EST performance with sustained gains in self‐efficacy. Trial Registration : The trial was prospectively registered in the University Hospital Medical Information Network Clinical Trials Registry (UMIN000044823).
  • Mitsushige Sugimoto, Tomoari Kamada, Masanori Ito, Junichi Iwamoto, Tadayoshi Okimoto, Shoko Ono, Takeshi Kanno, Toshimi Chiba, Kengo Tokunaga, Sachiyo Nomura, Takahisa Murao, Toshio Watanabe, Daisuke Asaoka, Eri Iwata, Ting Wang, Hideki Ono, Ryo Katsumata, Satoshi Kikuchi, Naoki Konishi, Satoshi Sato, Aya Sunago, Hiromi Sekiguchi, Hourin Cho, Daisuke Chinda, Osamu Dohi, Akinobu Nakata, Akira Higashimori, Yuka Hirashita, Keigo Misawa, Kazuhiro Mizukami, Daisuke Miyamori, Junko Mukohyama, Hideki Mori, Shuhei Yoshida, Jun Watanabe, Kiichi Satoh, Yuji Mizokami, Atsushi Takagi, Yoshifumi Takeyama, Susumu Eguchi, Sumio Watanabe, Hajime Isomoto, Takao Itoi, Satoshi Mochida
    Journal of Gastroenterology 2026年8月24日  
    Abstract In 2026, the fourth edition of the evidence-based clinical practice guidelines for peptic ulcer disease by the Japanese Society of Gastroenterology (JSGE) was revised. These revised guidelines cover epidemiology, hemorrhagic peptic ulcers, Helicobacter pylori eradication therapy, non-eradication therapy, drug-induced ulcers, non -H. pylori , and nonsteroidal anti-inflammatory drug (NSAID) ulcers, remnant gastric ulcers, surgical treatment, and conservative therapy for perforation and stenosis. Although H. pylori infection and NSAIDs use remain two major causes of peptic ulcers, the prevalence and mortality rates of peptic ulcer have been declining due to the widespread use of eradication therapy and development of potent acid-inhibitory drugs in recent years. However, an increasing trend in idiopathic ulcers and ulcers caused by non- H. pylori Helicobacter (NHPH) infection has attracted attention. In this revised edition, therapeutic algorithms for the treatment of peptic ulcers based on H. pylori infection, low-dose aspirin (LDA) or NSAID use, ulcer history, and ulcer complications (e.g., hemorrhage) remain largely unchanged. This edition shows options for H. pylori eradication in various situations compared with the previous edition, and recommends the most effective regimens, regardless of Japanese insurance coverage. In addition, a new flowchart outlining the eradication treatment process has been presented. Compared with the previous version, the main changes in pharmacological treatment have been made: due to its acid-inhibitory characteristics compared with proton pump inhibitors and increased evidence of its efficacy and safety, vonoprazan has now been selected as the first-line treatment for peptic ulcers and NSAID- and LDA-induced ulcers.
  • Rie Ono, Shin Takayama, Michiaki Abe, Ryutaro Arita, Koh Onodera, Kota Ishizawa, Takeshi Kanno, Natsumi Saito, Akiko Kikuchi, Takaaki Abe, Tadashi Ishii
    Frontiers in Medicine 13 2026年8月20日  
    Long COVID, a major post-acute infection syndrome (PAIS), characterized by prolonged or new-onset symptoms following acute COVID-19, critically affects patients' quality of life. Establishing easily measurable and objective biomarkers that reflect disease severity is essential for clinical management. This retrospective cohort study evaluated serum levels of growth differentiation factor 15 (GDF-15), a mitochondrial stress marker, and vascular cell adhesion molecule-1 (VCAM-1), a vascular endothelial stress marker, in 32 patients with Long COVID who presented with persistent systemic or neurological symptoms and had not required acute-phase hospitalization. Serum GDF-15, VCAM-1, and inflammatory cytokine levels were measured at the initial visit and at 3 and 6 months. Differences between patients who recovered at 6 months and those who did not (non-improved group) were analyzed using linear mixed-effects models (LMMs). Most inflammatory cytokines remained near their lower detection limits and were excluded from the longitudinal analysis. The LMMs revealed sustained elevation of both GDF-15 ( p = 0.02) and VCAM-1 ( p = 0.03) levels in the non-improved group. These findings suggest that longitudinal tracking of these two markers may offer clinically relevant insights into disease activity and treatment-resistant pathophysiology in mild acute-phase Long COVID.
  • Jun Watanabe, Hiromi Sekiguchi, Takeshi Kanno, Keigo Misawa, Satoshi Sato, Yuhong Yuan, Paul Moayyedi, Tomonori Yano, Atsushi Masamune, Tomoari Kamada
    Alimentary Pharmacology & Therapeutics 2026年8月10日  査読有り責任著者
    ABSTRACT Background Non‐ Helicobacter pylori ( H. pylori ), non‐nonsteroidal anti‐inflammatory drug (NSAID) peptic ulcer disease (PUD) is increasingly recognized as a distinct subgroup, but its proportion across clinical presentations remains unclear. Aim We aimed to estimate this proportion. Methods We searched MEDLINE, Embase and CENTRAL from their inception to March 2026 for observational studies. The primary outcome was the proportion of non‐ H. pylori , non‐NSAID PUD among adults with overall, bleeding and perforated PUD. Random‐effects meta‐analysis of logit‐transformed proportions was performed using restricted maximum likelihood. Meta‐regression assessed associations with study year, country‐level H. pylori prevalence and region. Protocol registered in PROSPERO (CRD420251174202). Results Overall, 92 studies (60,816 patients) from 32 countries were included. The pooled proportions of non‐ H. pylori , non‐NSAID PUD cases were 13.0% (95% confidence interval [CI], 10.4–16.2) in overall PUD, 11.3% (95% CI, 8.8–14.4) in bleeding PUD, and 22.0% (95% CI, 13.1%–34.7%) in perforated PUD. In univariable meta‐regression, a more recent study year was associated with a higher proportion of bleeding PUD ( β  = 0.076; 95% CI, 0.031–0.120). This association remained statistically significant after adjustment for country‐level H. pylori prevalence ( β  = 0.070; 95% CI, 0.026–0.113). Lower H. pylori prevalence was also associated with a higher proportion after further adjustment for region ( β  = −0.025; 95% CI, −0.046 to −0.005). Conclusion Non‐ H. pylori , non‐NSAID PUD represents a non‐negligible but heterogeneous component of PUD. In bleeding PUD, exploratory ecological analyses suggest a temporal increase, potentially reflecting evolving etiologic patterns beyond H. pylori infection and NSAID exposure.
もっとみる

MISC

 113
もっとみる

書籍等出版物

 15
もっとみる

講演・口頭発表等

 249
もっとみる

所属学協会

 9

共同研究・競争的資金等の研究課題

 16
もっとみる

産業財産権

 12
もっとみる

学術貢献活動

 12
もっとみる

社会貢献活動

 106

メディア報道

 1
  • テレビ、ラジオ、雑誌掲載など その他
    東北大学医学部広報、一條様のご助力にて一覧を作成しております。
一覧へ戻る